丁苯酞软胶囊联合多奈哌齐片治疗阿尔茨海默病的临床研究

发布时间：2018-03-05 13:06

本文选题：阿尔茨海默病　切入点：多奈哌齐　出处：《中国临床药理学杂志》2016年22期 　论文类型：期刊论文

【摘要】：目的观察丁苯酞软胶囊联合多奈哌齐片对阿尔茨海默病(AD)的近期疗效及安全性。方法 36例阿尔茨海默病患者随机分为对照组和试验组,每组18例。对照组每日口服多奈哌齐5 mg,试验组在对照组的基础上口服丁苯酞软胶囊0.2 g,每日3次。比较2组患者治疗前与治疗后3,6,9个月的简易智能状态检查量表(MMSE)、日常生活能力量表(ADL)、AD评估量表认知分量表(ADAS-cog)评分及C反应蛋白(CRP)、同型半胱胺酸(Hcy)水平。结果治疗后9个月,试验组MMSE评分为(18.17±1.43)分,对照组为(16.83±1.98)分,差异有统计学意义(P0.05)。治疗后6,9个月,试验组ADL评分分别为(46.78±5.22),(48.50±5.38)分,对照组ADL评分分别为(42.50±5.30),(43.83±5.21)分,差异有统计学意义(P0.05)。治疗后9个月,试验组CRP为(5.35±0.90)mg·L~(-1),对照组为(6.05±1.10)mg·L~(-1),差异有统计学意义(P0.05)。治疗后9个月,试验组Hcy为(13.83±1.46)μmol·L~(-1),对照组为(14.92±1.63)μmol·L~(-1),差异有统计学意义(P0.05)。药物不良反应主要表现为胃肠道反应、失眠、头晕,头痛、转氨酶升高等,试验组药物不良反应发生率为27.78%(5/18例),对照组为16.67%(3/18例),差异无统计学意义(P0.05)。结论多奈哌齐联合丁苯酞治疗阿尔茨海默病的近期疗效显著,可有效减缓患者认知功能和总体功能衰退进程。
[Abstract]:Objective to observe the efficacy and safety of butyphthalide soft capsule combined with Donepezil tablets in the treatment of Alzheimer's disease. Methods 36 patients with Alzheimer's disease were randomly divided into two groups: control group and experimental group. There were 18 cases in each group. The control group received 5 mg of Donepezil daily. The test group took butyphthalide soft capsule 0.2 g on the basis of the control group, 3 times a day. The scores of ADAS-cog) and the level of C-reactive protein (CRPU), homotypic cysteine cystatin (HcyA) in ADL / AD assessment scale were evaluated by MMSEN, ADL and AD assessment scales. Results after 9 months of treatment, there was no significant difference between ADAS-cog and ADAS-cog. The MMSE score of the trial group was 18.17 卤1.43, and that of the control group was 16.83 卤1.98. The difference was statistically significant (P 0.05). After treatment, the ADL scores of the test group were 46.78 卤5.22, 48.50 卤5.38), and the ADL scores of the control group were 42.50 卤5.30 and 43.83 卤5.21, respectively. The CRP of the trial group was 5.35 卤0.90 渭 mol 路L ~ (-1) and that of the control group was 6.05 卤1.10 mg 路L ~ (-1), the difference was statistically significant (P < 0.05). Nine months after treatment, the Hcy of the trial group was 13.83 卤1.46 渭 mol 路L ~ (-1) mol 路L ~ (-1), while that of the control group was 14.92 卤1.63 渭 mol 路L ~ (-1). The main adverse drug reactions were gastrointestinal reaction, insomnia, dizziness, headache, etc. The incidence of adverse drug reactions was 27.78 / 5 / 18 in the experimental group and 16.6767 / 3 / 18 in the control group, with no significant difference (P 0.05). Conclusion the short-term curative effect of Donepezil combined with butyphthalide in the treatment of Alzheimer's disease is significant. It can effectively slow down the process of cognitive and overall functional decline in patients.
【作者单位】：南京医科大学附属无锡人民医院老年医学科;南京医科大学附属无锡人民医院药学部;
【分类号】：R749.16

【相似文献】